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ABSTRACT The four dengue virus (DENV) serotypes are mosquito-borne flaviviruses
responsible for dengue fever and dengue hemorrhagic fever. People exposed to
DENV develop antibodies (Abs) that strongly neutralize the serotype responsible for
infection. Historically, infection with DENV serotype 4 (DENV4) has been less com-
mon and less studied than infections with the other three serotypes. However,
DENV4 has been responsible for recent large and sustained epidemics in Asia and
Latin America. The neutralizing antibody responses and the epitopes targeted
against DENV4 have not been characterized in human infection. In this study, we
mapped and characterized epitopes on DENV4 recognized by neutralizing antibodies
in people previously exposed to DENV4 infections or to a live attenuated DENV4
vaccine. To study the fine specificity of DENV4 neutralizing human antibodies, B cells
from two people exposed to DENV4 were immortalized and screened to identify
DENV-specific clones. Two human monoclonal antibodies (MAbs) that neutralized
DENV4 were isolated, and their epitopes were finely mapped using recombinant vi-
ruses and alanine scan mutation array techniques. Both antibodies bound to quater-
nary structure epitopes near the hinge region between envelope protein domain I
(EDI) and EDII. In parallel, to characterize the serum neutralizing antibody responses,
convalescence-phase serum samples from people previously exposed to primary
DENV4 natural infections or a monovalent DENV4 vaccine were analyzed. Natural in-
fection and vaccination also induced serum-neutralizing antibodies that targeted
similar epitope domains at the EDI/II hinge region. These studies defined a target of
neutralizing antigenic site on DENV4 targeted by human antibodies following natu-
ral infection or vaccination.
IMPORTANCE The four serotypes of dengue virus are the causative agents of den-
gue fever and dengue hemorrhagic fever. People exposed to primary DENV infec-
tions develop long-term neutralizing antibody responses, but these principally rec-
ognize only the infecting serotype. An effective vaccine against dengue should elicit
long-lasting protective antibody responses to all four serotypes simultaneously. We
and others have defined antigenic sites on the envelope (E) protein of viruses of
dengue virus serotypes 1, 2, and 3 targeted by human neutralizing antibodies. The
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epitopes on DENV4 E protein targeted by the human neutralizing antibodies and
the mechanisms of serotype 4 neutralization are poorly understood. Here, we report
the properties of human antibodies that neutralize dengue virus serotype 4. People
exposed to serotype 4 infections or a live attenuated serotype 4 vaccine developed
neutralizing antibodies that bound to similar sites on the viral E protein. These stud-
ies have provided a foundation for developing and evaluating DENV4 vaccines.
KEYWORDS Dengue virus serotype 4, human, neutralization, antibody responses,
epitope, infection, memory B cells, vaccination
Dengue virus (DENV) is a mosquito-borne positive-sense RNA virus belonging to theFlaviviridae family (1). Dengue is transmitted to people by Aedes aegypti or Aedes
albopictus mosquitoes (2, 3). Recent estimates indicate that nearly 400 million people
are infected worldwide each year, which makes dengue the most common and serious
vector-borne disease of humans (4).
While the majority of DENV infections are asymptomatic, symptomatic infections
can cause disease in a spectrum ranging from mild dengue fever to severe dengue
hemorrhagic fever and dengue shock syndrome (5). A primary DENV infection provides
lifelong protection against disease caused by the infecting homologous serotype in
most subjects (6). A secondary infection with virus of a heterologous serotype increases
the risk of developing severe dengue hemorrhagic fever (7). To understand the
molecular basis of a protective DENV antibody response, it is critical not only to map
the epitopes of strongly neutralizing human monoclonal antibodies (hMAbs) but also
to characterize the polyclonal neutralizing antibody responses to viruses of all the four
serotypes after natural infection. This knowledge is critical for evaluating antibody
responses to vaccination and improved second-generation vaccine design.
The DENV envelope (E) glycoprotein is required for viral binding and entry into cells
(8, 9). E protein is also the main target of neutralizing antibodies (10). The four serotypes
(DENV1 to DENV4) have variations of 25% to 40% in the amino acid sequence of the E
protein (11, 12). The E protein monomer consists of three domains (envelope protein
domain I [EDI], EDII, and EDIII), and two of these protomers form head-to-tail dimers in
viral particles. Three dimers lie parallel to each other in the particles, forming a raft (13,
14), and 30 of these rafts are arranged in a herringbone pattern on the mature virion.
Unlike the DENV neutralizing antibody response in mice, which principally targets
simple epitopes in EDIII (15, 16), nearly all human neutralizing antibodies target
complex quaternary structure E protein epitopes that are displayed on intact dengue
virions but not on soluble forms of E protein after natural infections (17, 18). Epitopes
of human type-specific neutralizing antibodies against DENV1, DENV2, and DENV3 have
been mapped to quaternary structure epitopes that span different E protein molecules
(18–21).
DENV4 has been less studied than the other serotypes. Kostyuchenko and col-
leagues recently solved a near-atomic-resolution structure of DENV4 (22). DENV4
surface E molecules are tightly packed compared to those of other serotypes, which
may explain the more rigid and stable nature of DENV4. DENV4 type-specific and
neutralizing MAb 5H2 was isolated from a chimpanzee infected with DENV4 (23). 5H2
binds to an epitope on the lateral ridge of EDI (23, 24). However, the epitopes targeted
by DENV4-specific antibodies in humans have not been characterized. The goal of the
current study was to map the antigenic sites on DENV4 recognized by antibodies in
people exposed to primary DENV4 infections or a monovalent live attenuated DENV4
vaccine.
RESULTS
DENV4 is neutralized by type-specific antibodies in human immune sera. To
study the properties of serum polyclonal DENV4 neutralizing human antibodies, we
assembled a panel of blood samples from people previously exposed to DENV4
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infections or people who had received a monovalent live attenuated DENV4 vaccine
(Table 1) (25, 26).
Individuals exposed to DENV have specific antibodies in circulation as well as
DENV-specific memory B cells (MBCs). Some of the DENV-specific antibodies in circu-
lation bind only to viruses of the serotype of the previous infection (type specific), while
others cross-react with two or more serotypes. Using serum samples from people
exposed to DENV4 natural infections or a monovalent live attenuated DENV4 vaccine,
we performed antibody depletion studies to determine the relative contributions of
serotype cross-reactive or type-specific antibodies to DENV4 neutralization. Polystyrene
beads coated with the homotypic (DENV4) or heterotypic (DENV2) DENV serotypes
were incubated with the immune serum samples to deplete specific populations of
antibodies. Depletion of antibodies was confirmed by enzyme-linked immunosorbent
assay (ELISA) before using the samples in DENV4 neutralization assays. Depleting the
DENV4 immune serum samples with the homotypic DENV4 antigen led to the removal
of nearly all the DENV-specific (serotype cross-reactive and DENV4 type-specific) anti-
bodies in the samples. As anticipated, depletions performed with DENV4 antigen led to
a large drop in levels of DENV4 neutralizing antibodies in both DENV4 infection and
vaccine sera (Fig. 1A and C and Table 2). Depleting DENV4 immune sera with hetero-
typic DENV2 antigen led to the removal of serotype cross-reactive but not of DENV4
type-specific antibodies. There was minimal to no reduction in neutralization of DENV4
in sera depleted with DENV2 antigen (Fig. 1B and D and Table 2). The control depletions
for subject 112 yielded different neutralization titers in the homotypic and heterotypic
depletions (1,263 versus 773). This could have been because these control depletions
were performed in separate experiments using different lots of the serum aliquots from
the same individual. However, the trends remained the same for the neutralization
titers against all four serotypes, with DENV4 titers being the highest in both cases.
Overall, these results demonstrate that type-specific antibodies were primarily
responsible for DENV4 neutralization in serum samples collected following natural
infection or monovalent DENV4 vaccination.
Isolation of DENV4 neutralizing human monoclonal antibodies. To further
characterize the B cell response to DENV4 infection, we transformed B cells from two
DENV4-immune individuals (subjects 002 and 112) and isolated hMAbs, as previously
described (27). The transformed B cell culture supernatants were screened for binding
to DENV4. On the basis of the number of positive wells and the number of transformed
TABLE 1 Panel of DENV immune sera
Serum type Serum Yr of infection
Location of
infection
Time between infection
and blood draw (yrs)
Reciprocal of Neut50 titers against DENV1
to DENV4a
DENV1 DENV2 DENV3 DENV4
DENV4 immune
sera
002 1994 Guatemala 15 20 20 29 77
102 2007 Honduras 2 20 20 41 159
112 2001 Nicaragua 2 128 346 175 1,639
07/333 Unknown Thailand Unknown 20 153 367 >1,280
06/302 Unknown Thailand Unknown 20 32 60 >1,280
06/105 Unknown Thailand Unknown 20 26 91 685
DENV2 immune
serum
08/90 Unknown Thailand Unknown 20 >1,280 60 32
DENV3 immune
serum
118 2009 Nicaragua 1 60 32 980 76
DENV4 vaccine
immune serab
256.03.36 20 20 20 142
256.03.38 20 20 20 148
256.03.57 20 20 20 144
256.03.68 20 20 20 988
aThe Neut50 titer values in bold signify the highest Neut50 reciprocal titers for each sample. Each value depicts the mean Neut50 titer from two replicates.
bThe DENV4 vaccine immune sera represent vaccinations performed in 2009.
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B cells tested (determined by average colony counts in transformed wells), the fre-
quencies of DENV-specific B cells in circulation were estimated to be 0.19% and 0.20%
of transformable B cells for subjects 002 and 112, respectively. Previously, it was
reported that there may be a long-term set point frequency of about 0.1% to 0.2%
DENV-specific B cells in the circulating memory B cell pool following DENV infection
(28), and the frequencies of 0.19% and 0.20% in the two subjects studied here are
consistent with those previous estimates. Note that, even though the frequencies of
DENV4-specific B cells determined for subjects 002 and 112 were similar, their serum
titers were different. As mentioned above, the B cell response to primary DENV
infection is a mix of DENV serotype cross-reactive and type-specific antibodies. More-
FIG 1 DENV4 is neutralized by type-specific antibodies in human primary infection immune sera or vaccine
immune sera. Primary DENV4-immune serum sample 112 (A and B) and DENV4 NIH monovalent vaccine serum
sample 256.01.36 (C and D) were depleted of antibodies binding to DENV4 antigen (A and C) or DENV2 antigen (B
and D). Control depletions were performed using bovine serum albumin as an antigen. Results presented here for
antibody depletions are representative of data obtained with three primary DENV4 immune sera and four DENV4
monovalent vaccine sera (Table 2). Results are from 2 technical replicates in one experiment. Each point represents
the mean neutralization value from the two replicates, and the error bars depict the standard deviations.
TABLE 2 DENV4 neutralization by human immune sera depleted of DENV binding antibodiesa
Serum type Sample ID
Homotypic depletionb Heterotypic depletionc
Control depleted
(Neut50)
DENV4 depleted
(Neut50)
% loss of
neutralization
(mean  SD)
Control depleted
(Neut50)
DENV2 depleted
(Neut50)
% loss of
neutralization
(mean  SD)
DENV4 immune
sera
002 58 20 100 82 84 0
102 112 43 62 113 98 13
112 1,263 20 100 773 827 0
DENV4 vaccine
immune sera
256.03.36 175 20 100 175 142 19
256.03.38 61 20 100 61 83 0
256.03.57 53 20 100 98 75 23
256.03.68 425 160 62 409 271 34
aA U937DC-SIGN flow cytometry-based neutralization test was performed on human DENV4 immune sera depleted of DENV4 (homotypic) or DENV2 (heterotypic)
binding antibodies, and Neut50 (i.e., the dilution factor required to neutralize 50% of infection) values against DENV4 were calculated in these depleted immune sera.
Percent loss of neutralization was calculated as follows: % loss of neutralization  100  [(DENV-depleted Neut50/control-depleted Neut50)  100]. The mean
percentages of loss in neutralization between homotypic and heterotypic depletions in both naturally infected and vaccine immune sera were significant (P  0.01
and P  0.001, respectively) by two-sample t tests performed to compare the percentages of loss of neutralization between homotypic and heterotypic depletions in
both naturally immune and vaccinated serum samples. Each value represents the mean Neut50 titer from two replicates.
bAverage for DENV4 immune sera, 87  18; average for DENV4 vaccine immune sera, 4  8.
cAverage for DENV4 immune sera, 91  19; average for DENV4 vaccine immune sera, 19  12.
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over, a relatively small fraction of the virus-specific B cells produce neutralizing Abs
(29–31). The serum neutralizing Abs are derived from long-lived plasma cells (LLPCs) in
the bone marrow and not the memory B cell compartment. Previous studies have also
reported a weak and inconsistent correlation between DENV-specific or other viral
antigen-specific antibody titers in the serum and the frequency of antigen-specific
memory B cells in the blood (32–34).
We also determined the DENV serotype specificity of all the positive B cell culture
supernatants from subject 112. Of the 34 DENV antigen-reactive supernatants, anti-
bodies in 32% bound only to DENV4 (type-specific) and in 68% bound to two or more
serotypes (cross-reactive). From the EBV-transformed B cell lines secreting DENV
antigen-reactive antibodies, we isolated 8 human B cell hybridoma cell lines, as
previously described (28). Two cell lines, designated D4-126 and D4-131, secreted
DENV4 type-specific and neutralizing hMAbs with Neut50 values (defined as the dilution
factor required to neutralize 50% of infection) of 0.54 g/ml and 0.43 g/ml, respec-
tively (Fig. 2A). Both of these antibodies were isolated from subject 002. To characterize
the binding properties of D4-126 or D4-131 hMAbs further, we performed binding
assays with whole DENV4 virions, recombinant E (rE) or rEDIII proteins of DENV4, and
increasing concentrations of hMAb D4-126 or D4-131. The two hMAbs bound to whole
DENV4 particles similarly (Fig. 2B). HMAb D4-126 did not bind to rE protein, whereas
D4-131 exhibited low levels of binding to rE protein at high concentrations (10
g/ml) (Fig. 2B). The hMAbs did not bind to rEDIII protein (Fig. 2B). These studies
revealed that neutralizing hMAb D4-126 or D4-131 bound best to intact DENV4 virions.
However, it is also possible that MAb D4-126 or D4-131 could bind to E dimers formed
from rE monomers at higher concentrations as demonstrated by the D4-131 MAb
binding to rE at higher concentrations.
FIG 2 DENV4 neutralizing hMAb D4-126 or D4-131 preferentially binds to epitopes displayed on intact virions. (A) U937DC-SIGN flow
cytometry-based neutralization assays were conducted to determine the neutralization of DENV1 to DENV4 by D4-126 or D4-131.
Results are from 2 technical replicates in an experiment. Each point represents the mean neutralization value from the two replicates,
and the error bars depict the standard deviations. Neutralization experiments were repeated at least twice. (B) Binding to DENV4 whole
virions, recombinant E protein ectodomain (rE), and recombinant E protein domain III (rEDIII) by D4-126 or D4-131 was tested in an
ELISA. Results are from 2 technical replicates in one experiment. Each point represents the mean from the two replicates, and the error
bars depict the standard deviations OD, optical density.
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Additionally, these antibodies were not cross-reactive to the Zika virus (H/PF/2013
and MR 766 strains) and remained type specific to DENV4.
hMAb neutralization of different DENV4 strains. To determine if hMAbs D4-126
and D4-131 neutralized diverse strains of DENV4, we used a panel of recombinant
isogenic DENV4 expressing the E protein from different DENV4 genotypes and labora-
tory strains (Table 3). The hMAbs equally neutralized all variants tested, except for a
Cambodia 2010 genotype I (GI) strain, which was not neutralized by D4-126 and was
neutralized less efficiently by D4-131 than by other strains tested (Fig. 3).
Mapping the epitopes of DENV4 neutralizing hMAbs. Human DENV1, DENV2,
and DENV3 type-specific neutralizing antibodies often bind to quaternary structure
epitopes centered on the EDI/II hinge (17–19, 21, 38) and/or the EDIII region (2, 20, 21,
39, 40). Recently, we demonstrated that it is possible to recover recombinant chimeric
DENVs displaying E protein domains or epitopes from viruses of two different serotypes
(38, 39). We used a rDENV4 strain with a mutated EDI/II hinge region and EDII region
(rDENV4/3) to map the binding sites of hMAbs D4-126 and D4-131 (Fig. 4A and B). The
recombinant virus has 25 amino acid replacements at different positions that are
highlighted in green (Fig. 4A and B) (unpublished data). We did not detect any binding
or neutralizing activity for the hMAb D4-126 or D4-131 with the rDENV4/3, indicating
that the DENV4 EDI/II hinge residues are part of the epitope recognized by these MAbs
(Fig. 4C and D).
As an alternative approach to mapping the epitopes of D4-126 and D4-131, both
hMAbs were screened by shotgun mutagenesis against a comprehensive mutation
library in which nearly every residue within the precursor membrane (prM) and E was
individually mutated to alanine, as described previously (35). Residues were identified
as critical to binding of the DENV4 hMAb if they did not bind to the DENV4 hMAb but
did bind to other conformation-dependent MAbs. Six amino acids (K51, V53, K124,
L135, K200, and K234) in the EDI/II hinge and EDII regions were critical for binding of
D4-126 (Fig. 4E). K51, V53, K124, and K200 were among the residues that were altered
TABLE 3 Characteristics of DENV4 strains used in this study
Virus Genotype Reference or source
GenBank
accession no.
TVP-376 II 35 KC963424
Sri Lanka 1992 II 36 KJ160504.1
Puerto Rico 1999 II GenBank database FJ882599.1
Cambodia 2010 I GenBank database KF543272.1
Malaysia 1973 Sylvatic 37 JF262780
FIG 3 Neutralization of different DENV4 strains by hMAb D4-126 or D4-131. U937DC-SIGN flow cytometry-based neutralization assays were conducted to
compare the abilities of D4-126 (A) and D4-131 (B) hMAbs to neutralize different laboratory-adapted or clinical strains of DENV4. The MAbs neutralized all
variants except for the Cambodia 2010 genotype I strain, which was not neutralized by D4-126 and was neutralized less efficiently by D4-131 than by the other
strains. Results are from 2 technical replicates in one experiment. Each point represents the mean neutralization value from the two replicates, and the error
bars depict the standard deviations.
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in rDENV4/3. Four amino acids (K51, K124, K200, and K202) within the EDI/II hinge and
EDII region were critical for binding of D4-131 (Fig. 4F). K51, K124, and K200 were
among the residues that were altered in rDENV4/3. These data validated our observa-
tions that the EDI/II hinge region residues are critical for binding of D4-126 and D4-131
and also indicated that the epitopes differ slightly between the two hMAbs.
FIG 4 The EDI/II hinge region is important for the binding and neutralization of DENV4 by hMAbs D4-126 and D4-131. (A) Amino acid alignment of DENV4 and
rDENV4/3 E protein sequence in the EDI/II hinge; EDII regions with mutated residues are colored in green. (B) Recombinant DENV4 containing EDI/II hinge; EDII residues
fromDENV3 (rDENV4/3) used tomap the epitopes of hMAbs D4-126 and D4-131 are shown. The figure depicts amodel of the DENV4 E protein dimer, with themutated
residues colored in green. (C) Binding of hMAbs D4-126 and D4-131 to DENV4, DENV3, or rDENV4/3. (D) DENV4 and rDENV4/3 neutralization by hMAbs D4-126 and
D4-131. Results are from 2 technical replicates in an experiment. Each point represents the mean from the two replicates, and the error bars depict the standard
deviations. Mapping of the critical residues for D4-126 and D4-131 was performed by shotgun mutagenesis by screening for loss of MAb binding to a DENV4 alanine
scan mutation array. Critical residues are visualized as magenta spheres on the DENV E dimer structure (PDB identifier [ID] 1OAN). (E) Six critical residues were identified
for D4-126 in the E protein DII and DI/II hinge region. (F) Four critical residues were identified for D4-131 in the E protein DII and DI/II hinge region.
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DENV4 neutralizing hMAbs define epitopes targeted by serum antibodies in
DENV4-immune individuals. HMAbs D4-126 and D4-131 were isolated from circulat-
ing memory B cells. Serum antibodies are generally thought to derive from secretion of
long-lived plasma cells (LLPCs) residing in the bone marrow. To determine if DENV4
polyclonal serum neutralizing antibodies in immune sera also targeted the D4-131 and
D4-126 epitopes, we performed competition-binding assays with DENV4 immune
serum samples and labeled DENV4-specific MAbs. As depicted in Fig. 5, DENV4 immune
sera effectively blocked the binding of each of the MAbs, whereas DENV2 or DENV3
immune sera had marginal effects on MAb binding. The magnitude of the DENV4
immune responses (based on their neutralization titers for DENV4) in serum samples
correlated with the ability to block 50% of the binding of D4-126 or D4-131. These
findings indicated that there are antibodies in DENV4 polyclonal immune serum
samples that bind to sites similar to those that overlap tightly with the epitopes
recognized by hMAbs D4-126 and D4-131.
To further assess the epitope specificity of functionally neutralizing antibodies in
DENV4 sera collected following infection or experimental vaccination, we performed
neutralization assays with rDENV4/3, which had lost the epitopes recognized by hMAbs
D4-126 and D4-131. Neutralization assays using the rDENV4/3 strain were performed
with sera from six subjects with prior natural DENV4 infection and sera from 4 subjects
previously immunized with a DENV4 live attenuated vaccine. The percent loss of
neutralization was calculated as follows: percent loss of neutralization  100 
[(rDENV4/3 Neut50/DENV4 Neut50)  100] (Table 4). Sera from both types of immune
donors neutralized the rDENV4/3 strain less efficiently than sera from wild-type (WT)
DENV4, although to differing extents. The mean percentages of loss in neutralization
with rDENV4/3 in both naturally infected immune sera and vaccine sera were significant
(P  0.005 and P  0.002, respectively) by one-sample t test. Of the six DENV4
postinfection sera tested, those from three subjects (002, 102, and 07/333) showed a
60% loss in neutralization against rDENV4/3, while the remaining infection sera
displayed a more modest or no detectable reduction in neutralization (Fig. 6A). All of
the vaccine sera tested also showed a60% loss in neutralization against the rDENV4/3
strain (Fig. 6B). These results suggested that the EDI/II hinge region is a target of
polyclonal type-specific DENV4 neutralizing antibodies.
DISCUSSION
Sustained humoral immunity depends on LLPCs to maintain protective levels of
antibody in serum and on MBCs, which comprise a subset of cells poised to expand and
adapt in response to subsequent exposure to the infecting pathogen (41). In this study,
we characterized the properties of MBC- and LLPC-derived human antibodies that
neutralize DENV4. Although people exposed to DENV4 infections developed serotype
FIG 5 DENV4 immune sera block the binding of hMAb D4-126 or D4-131 to DENV4. Blockade of binding assays was performed with DENV
immune sera for MAb D4-126 (A) or MAb D4-131 (B). Blockade assays were performed using 2 primary DENV4 immune sera (002 and 112),
a primary DENV2 immune serum (08/90), or a primary DENV3 immune serum (118). The epitope-specific response in the serum samples
was calculated by determining the serum dilution factor that led to a 50% reduction in hMAb binding to DENV4. Each value depicts the
mean blockade of binding from two replicates in an experiment. Each point represents the mean from the two replicates, and the error
bar depicts the standard deviation.
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cross-reactive and type-specific antibodies, our results show that the type-specific
antibodies were the principal determinants of neutralization of DENV4. Using MAbs
isolated from the MBCs of people exposed to DENV4, we identified epitopes centered
on the EDI/II hinge as the target of DENV4 neutralizing antibodies. In people exposed
to DENV4 infections or a live attenuated vaccine candidate, both MBC- and LLPC-
derived polyclonal neutralizing antibodies also recognized epitopes centered on the
EDI/II hinge of DENV4.
Substantial progress has been made in understanding the epitopes targeted by
human antibodies that neutralize DENV serotypes 1, 2, and 3 (2, 18–21, 30), whereas
serotype 4 is relatively less studied. The two DENV4 neutralizing MAbs whose results are
reported in this study were sensitive to changes in or near the EDI/II hinge region. The
hinge region plays a critical role in the conformational change that the E protein
undergoes at low pH to fuse to the endosomal membrane allowing viral uncoating and
the release of viral RNA into the cellular cytoplasm (42). Because these epitopes are
located in this region, it is reasonable to hypothesize that these DENV4 hMAbs act by
FIG 6 The DENV4 EDI/II hinge region is a target of neutralizing antibodies in people exposed to DENV4 infection or to an experimental vaccine. A
U937DC-SIGN flow cytometry-based neutralization assay was performed with primary DENV4 infection sera (A) or DENV4 monovalent vaccine sera (B) and
WT DENV4 or rDENV4/3. The 50% neutralization (Neut50) titers were calculated and plotted. Values corresponding to loss of neutralization against rDENV4/3
for each sample are indicated. Samples that did not block 50% of infection at the highest concentration were assigned a value of 5. Results are from 2 technical
replicates in one experiment. Each point represents the mean neutralization value from the two replicates.
TABLE 4 Percent loss in neutralization of polyclonal DENV4 immune and vaccine sera
against rDENV4/3a
Serum type
Serum
sample
Reciprocal of Neut50 titers
against DENV4 and
rDENV4/3
% loss in
neutralizationDENV4 rDENV4/3
DENV4 immune
sera
002 115 44 62
102 153 31 80
112 1,746 1,609 8
07/333 1,256 399 69
06/302 1,660 1,058 37
06/105 399 204 49
DENV4 vaccine
immune sera
256.03.36 562 178 69
256.03.38 255 5 98
256.03.57 153 5 97
256.03.68 1,167 276 76
aA U937DC-SIGN flow cytometry-based neutralization assay was performed with primary DENV4 infection
sera or DENV4 monovalent vaccine immune sera and WT DENV4 or rDENV4/3 viruses. Neut50 titers were
calculated. Samples that did not block 50% of infection at the highest concentration were assigned a value
of 5. The mean percentages of loss in neutralization with rDENV4/3 in both naturally infected immune sera
and vaccine sera were significant (P  0.005 and P  0.002, respectively) by a one-sample t test performed
to evaluate the relative (percent) difference scores created from the paired loss-of-neutralization data.
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preventing conformational changes in the E protein required for fusion, entry, and
initiation of a productive viral infection.
As reported previously with DENV3 natural isolates (43), some DENV4 epitopes
targeted by neutralizing mouse MAbs differ in potency depending on the DENV4
genotype (35). We evaluated if hMAb D4-126 and D4-131 effectively neutralized
different strains of DENV4. All strains studied here were neutralized well, except for one
GI strain (Cambodia 2010) that was resistant and partially resistant to hMAb D4-126 and
D4-131, respectively. Three of the 16 amino acids differing between the E proteins of
Sri Lanka 1992 (GII) and the Cambodian 2010 (GI) in EDII (L122S, T203K, and H233Y)
overlapped with the region identified by shotgun mutagenesis as representing the
binding sites of D4-126 and D4-131. We propose that natural variation between DENV4
strains leads to poor or altered binding of D4-126 and D4-131 and neutralization
escape. Moreover, recent studies demonstrated that the virion particles of some DENV
strains flex and “breathe” more than those of other strains, which can also lead to better
exposure of partially hidden epitopes (35, 44, 45). Differences in amino acid sequences
outside the main footprints of D4-126 and D4-131 also may alter epitope exposure
indirectly and contribute to strain-specific differences in neutralization sensitivity.
The LLPC-derived polyclonal serum antibodies likely provide the first line of defense
against reinfection in vivo. Our studies using blockade of antibody binding demon-
strated that the DENV4 polyclonal immune sera contained antibodies that specifically
blocked the binding of MAbs D4-126 and D4-131 to their epitopes. Additionally, a
recombinant DENV4 strain missing the D4-126 and D4-131 epitopes was less sensitive
than WT DENV4 to neutralization by DENV4 infection or vaccine immune sera. These
results establish that the regions/epitopes defined using MAbs are targets of the
LLPC-derived polyclonal serum antibody response as well. In some individuals, a
fraction or most of the serum DENV4 neutralizing antibody response was unaffected by
EDI/II hinge mutations, indicating that other regions and epitopes are likely involved in
DENV4 neutralization. Chimpanzee DENV4 type-specific strongly neutralizing MAb 5H2
is directed to the EDI region (23). Cockburn et al. demonstrated that at least a portion
of the antibodies in DENV4 convalescent patient sera bound to epitopes on DI that
overlapped with that of the MAb 5H2 footprint (24). Hence, our findings, while
providing good insights into the DENV4 neutralizing antibody responses, clearly em-
phasize the need for further analyses of the polyclonal serum neutralizing antibody
responses using a larger panel of DENV4 immune sera. There is also a need to finely
map the epitopes of the other neutralizing antibodies against DENV4 to draw broader
and more generalizable conclusions about the DENV4 serum neutralizing antibody
responses.
In summary, we propose that the EDI/II hinge region is a target of DENV4 neutral-
izing human antibodies in both the MBC and LLPC compartments. The EDI/II hinge
region is also a target of human type-specific antibodies that neutralize DENV1 and
DENV3. Our observations have implications for understanding the mechanisms of
DENV4 neutralization, evaluating new vaccine candidates, and developing next-
generation vaccines.
MATERIALS AND METHODS
Cells. Aedes albopictus C6/36 cells (American Type Culture Collection; CRL-1660) were maintained in
minimal essential medium (MEM; Gibco) at 32°C. Vero cells (American Type Culture Collection; CCL-81)
were maintained in Dulbecco’s modified Eagle’s medium-F12 (DMEM-F12) at 37°C. A human monocyte
lymphoma cell line (U937) (American Type Culture Collection; CRL-1593.2) ectopically expressing den-
dritic cell (DC)-specific intercellular adhesion molecule-3-grabbing nonintegrin DC-SIGN (U937DC-
SIGN) (46, 47) was maintained in RPMI 1640 (Gibco) medium supplemented with 50 mM beta-
mercaptoethanol at 37°C. U937 DC-SIGN cells were kindly provided by the laboratory of Mark Heise at
the University of North Carolina, Chapel Hill. All growth and maintenance media used were supple-
mented with 5% fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 0.1 mM
nonessential amino acids (Gibco), and 2 mM glutamine. All cells were incubated in the presence of 5%
CO2. The 5% FBS was reduced to 2% to make infection medium for each cell line.
Ethics statement. Convalescent DENV immune blood samples were collected from travelers visiting
countries in which dengue is endemic. The protocol for obtaining dengue immune blood samples was
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approved by the Institutional Review Board of the University of North Carolina at Chapel Hill (protocol
08-0895). Written informed consent was obtained from all subjects before their participation in the study.
DENV immune sera. DENV serum samples used in this study were obtained from the previously
existing dengue traveler collections as mentioned above. The samples were not from acute clinical
patient samples and hence were not PCR confirmed. DENV4 immune sera were also obtained from
people who had received a live attenuated monovalent DENV4 vaccine (25, 26) developed by the US
National Institutes of Health (NIH) and were provided by Anna Durbin and Stephen Whitehead. All
samples were coded and analyzed anonymously.
Viruses, rE, and rEDIII. DENV1 (American genotype; strain West Pac74), DENV2 (Asian genotype;
strain S-16803), DENV3 (Asian genotype; strain CH-53489), and DENV4 (American genotype; strain
TVP-376) (provided by Robert Putnak, Walter Reed Army Institute of Research, Silver Spring, MD) were
used for both binding enzyme-linked immunosorbent assays (ELISAs) and neutralization assays. All
viruses used in the neutralization assays were grown in C6/36 Aedes albopictus mosquito cells at 32°C, as
previously described (48). DENV4 was purified in our laboratory as previously described (16). Purified live
DENV2 was purchased from Microbix Biosystems, Inc. (Mississauga, Ontario, Canada). Recombinant
envelope (rE) proteins (80% of E protein) from each of the four serotypes were produced within our
laboratory or purchased from Hawaii Biotech, Inc. (49). Recombinant EDIII proteins were produced within
our laboratory as described previously (50).
Depletion of DENV4-specific antibodies from human immune sera collected from subjects with
prior DENV4 infection or vaccination. Purified DENV was absorbed onto 4.5-m-diameter Polybead
polystyrene microspheres (Polysciences, Inc.) at a bead (microliters) to ligand (micrograms) ratio of 5:2.
Polystyrene beads were washed three times with 0.1 M borate buffer (pH 8.5) and incubated with the
relevant purified DENV (DENV4 for homotypic depletions and DENV2 for heterotypic depletions) over-
night at room temperature (RT). Control beads were incubated overnight with an equivalent amount of
bovine serum albumin (BSA). The control and virus-adsorbed beads were blocked with BSA (10 mg/ml)–
borate buffer for 30 min at RT three times and washed four times with phosphate-buffered saline (PBS).
DENV4 immune sera from naturally infected individuals or NIH vaccine candidate recipients were
depleted of virus-specific antibodies by incubating the samples with virus-adsorbed beads for 1 h at 37°C
with end-over-end mixing. Samples were subjected to at least three sequential rounds of depletions
before successful removal of the respective antibodies was confirmed by ELISA. The ability of the
depleted samples to neutralize viruses of all of the four serotypes was tested after the confirmation ELISA.
Generation of DENV4-specific MAbs. Previously cryopreserved peripheral blood mononuclear cells
(PBMCs) isolated from blood samples collected as part of the dengue traveler studies were thawed
rapidly in a 37°C water bath and washed prior to transformation with Epstein-Barr virus (EBV) contained
in the clarified supernatants from cultures of B95.8 cells (ATCC VR-1492) and incubated with CpG and
additional supplements, as described previously (27, 51). Cultures were incubated at 37°C with 5% CO2
for 10 days prior to screening for DENV4-reactive cell lines with ELISA. The minimal frequency of
DENV4-reactive B cells was estimated on the basis of the number of wells with DENV4-reactive
supernatants compared to the total number of lymphoblastoid cell line (LCL) colonies in the transfor-
mation plates as follows: (number of wells with DENV4-reactive supernatants)/(number of LCL colonies
in the plate). Cells from wells with supernatants reacting in the DENV4 capture ELISA were subjected to
cytofusion, as previously described (27, 51). Following cytofusion, hybridomas were selected for growth
in hypoxanthine-aminopterin-thymidine (HAT) medium containing ouabain. Wells containing hybrid-
omas producing DENV4-reactive antibodies were cloned biologically by 3 rounds of limiting dilution
plating. Once clonal, the cell lines were used to produce MAb immunoglobulin G (IgG) in cell superna-
tants, using serum-free medium, followed by protein G column purification.
Virus, rE, and rEDIII ELISA. Equivalent quantities of DENV (as previously titrated by ELISA) were
captured by anti-E mouse MAb 4G2, or rE proteins were directly coated (rE, 100 ng/well; rEDIII, 200
ng/well) on ELISA plates overnight at 4°C (39). Plates were blocked with 3% (vol/vol) normal goat serum
(Gibco, Thermo Fisher, USA)–Tris-buffered saline (TBS)–0.05% (vol/vol) Tween 20 (blocking buffer).
Primary antibodies were diluted serially to generate a range of concentrations. Alkaline phosphatase-
conjugated secondary antibodies were used to detect binding of primary antibodies with p-nitrophenyl
phosphate substrate, and reaction color changes were quantified by spectrophotometry.
Blockade of binding assays. Assays for blockade of binding were performed as described previously
(52, 53). Briefly, DENV4 was captured using mouse anti-E MAb 4G2 and was blocked as described above.
Serial dilutions of DENV serum were added to the DENV4-coated plates and incubated at 37°C for 1 h.
The plates were washed, and alkaline phosphatase-conjugated DENV4 hMAbs were added and incubated
at 37°C for 1 h. P-nitrophenyl phosphate substrate was added, and reaction color changes were
quantified by spectrophotometry. Percentages of blockade of binding were calculated as follows: [100
(optical density of sample/optical density of control)  100].
Flow cytometry-based U937DC-SIGN neutralization assay. Neutralization potentials of the
DENV4 immune sera and hMAbs were measured using a flow cytometry-based neutralization assay with
U937DC-SIGN cells as previously described (17). Briefly, virus and antibody mixtures or sera were
incubated for 1 h at 37°C, prior to the addition of U937DC-SIGN cells. After 2 h of incubation, cells were
washed twice with infection media. Cells then were fixed and permeabilized 24 h after infection and
probed with 2H2 (anti-prM MAb) conjugated to Alexa-Fluor 488, and the percentage of infected cells was
determined using a Guava flow cytometer (FC) (EMD Millipore). Stained cells were analyzed to calculate
50% neutralization titers.
Construction of rDENV strains. rDENV4/3 was generated as previously described (39). Briefly, the
DENV4 genome (Sri Lanka 1992; GenBank accession no. KJ160504.1) (36) was split into 4 separate
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plasmids (plasmids A, B, C, and D), allowing production of genomic cDNA. Plasmids were digested, and
genome fragments were ligated together into a full-length cDNA genome from which RNA transcripts
were derived. These transcripts were electroporated into cells, and cell culture supernatant containing
viable virus was harvested. Virus was passaged two times on C6/36 cell monolayer cultures and stored
at 80°C. To generate rDENV, the nucleotide sequence of the E glycoprotein was changed to alter the
amino acid residues. rDENV4/3 contains EDI/II hinge residues (with 25 amino acids altered) from DENV3
(Fig. 4A) (Sri Lanka 1989, designated UNC3001; NCBI accession no. JQ411814.1) (43).
Generation of DENV4 strains displaying diverse E glycoproteins. In order to examine genetic
diversity within a serotype, a panel of near-isogenic rDENV4 was generated by replacing the E gene of
WT genotype II infectious clone virus (Sri Lanka 1992; accession no. KJ160504.1) (36) with E glycoprotein
genes representing diverse strains within DENV4. Subgenomic A plasmids encoding E protein genes only
were synthesized (all other proteins were encoded by genes based on DENV Sri Lanka 1992) representing
genotype I (GI) (Cambodia 2010; NCBI accession no. KF543272.1) (V. Duong, S. Lay, and P. Buchy,
unpublished data) or genotype II (GII) (Puerto Rico 1999; NCBI accession no. FJ882599.1), available in
GenBank database (http://www.ncbi.nlm.nih.gov/nuccore/228539113) or a sylvatic E protein sequence
(Malaysia 1973; NCBI accession no. JF262780) (37). Recombinant subgenomic A plasmids were synthe-
sized, and then viral assembly and rescue were performed as described above for generation of rDENV4.
Shotgun mutagenesis epitope mapping. Shotgun mutagenesis epitope mapping was performed
as described previously (35). Briefly, a DENV4 prM-E protein expression construct was subjected to
high-throughput alanine scanning mutagenesis to generate a comprehensive mutation library (with each
residue mutated to alanine and alanine residues mutated to serine). Expression plasmids encoding the
mutant proteins (97% coverage) were generated and arrayed into 384-well plates. Mutants were
transfected into HEK-293T cells (American Type Culture Collection CRL-3216) and allowed to express for
22 h. Cells were fixed in 4% (vol/vol) paraformaldehyde (Electron Microscopy Sciences) and permeabil-
ized with 0.1% (wt/vol) saponin (Sigma)–PBS containing calcium and magnesium. Cells were stained with
purified anti-DENV4 hMAbs (D4-126 and D4-131) diluted in 10% normal goat serum (NGS; Sigma)–0.1%
saponin (pH 9.0). Antibody binding was detected using Alexa Fluor 488-conjugated secondary antibody
(Jackson ImmunoResearch Laboratories)–10% NGS (Sigma)–0.1% saponin. Cells were washed three times
with PBS supplemented with 0.1% saponin, 1 mM MgCl2, and CaCl2 followed by two washes in PBS. The
mean cellular fluorescence was detected using a high-throughput flow cytometer (HTFC; Intellicyt).
Mutations were identified as critical to the hMAb epitope if they did not bind the test hMAb but did bind
other conformation-dependent MAbs. This counter-screen strategy facilitated the exclusion of E mutants
that were locally misfolded or had expression defects (54).
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